Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Biologic Acquires Another Plasma-based Pharma

publication date: Oct 16, 2008

China Biologic Products continued on its acquisitive path by announcing its intention to purchase a 35% stake in Xi'an Huitian Blood Products Co., Ltd. Both companies manufacture plasma-based pharmaceuticals. China Biologic will pay 44 million RMB ($6.4 million) for the purchase of Huitian. Two weeks ago, China Biologic announced a $28.5 million deal under which it will acquire a 50% controlling interest in Qianfeng Biological Products of Guizhou Province, also a plasma-based pharma. More details...
Stock Symbol: (OTCBB: CBPO)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital